| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | -$106K | -107.3% | -142.6% |
| R&D Expense | $1.8M | -9.8% | +10.5% |
| SG&A Expense | $3.3M | -14.9% | +58.2% |
| Operating Income | -$5.2M | -17.0% | -48.9% |
| Pre-tax Income | -$5.2M | -18.0% | -53.7% |
| Net Income | -$5.2M | -18.0% | -53.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $191K | -82.3% | -14.4% |
| Current Assets | $6.4M | -44.2% | -51.0% |
| Total Assets | $10.7M | -32.2% | -38.6% |
| Current Liabilities | $1.8M | -35.6% | -3.2% |
| Total Liabilities | $1.8M | -35.6% | -3.2% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.8M | — | -336.6% |
| Investing Cash Flow | -$2K | — | — |
| Financing Cash Flow | $8.2M | — | — |
| $8.9M |
| -31.4% |
| -42.8% |